Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.

Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Litzow MR, Porrata LF, Winters JL, Kumar S.

Biol Blood Marrow Transplant. 2013 Jan;19(1):87-93. doi: 10.1016/j.bbmt.2012.08.010. Epub 2012 Aug 23.

2.

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.

3.

Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.

Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK.

Transfusion. 2011 Oct;51(10):2175-82. doi: 10.1111/j.1537-2995.2011.03136.x. Epub 2011 Apr 14.

PMID:
21492180
4.

Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK.

Bone Marrow Transplant. 2011 Jan;46(1):64-9. doi: 10.1038/bmt.2010.78. Epub 2010 Apr 12.

PMID:
20383210
5.

Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.

Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK.

Transfusion. 2012 Nov;52(11):2375-81. doi: 10.1111/j.1537-2995.2012.03579.x. Epub 2012 Mar 8.

PMID:
22404694
6.

Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.

Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K, Silva M, Steinberg M, Matous J, Selvey S, Maris M, McSweeney PA.

Biol Blood Marrow Transplant. 2011 May;17(5):729-36. doi: 10.1016/j.bbmt.2010.08.018. Epub 2010 Oct 14.

7.

Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.

Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED.

Pharmacotherapy. 2012 Jul;32(7):596-603. doi: 10.1002/j.1875-9114.2012.01096.x.

PMID:
22760691
8.

Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.

Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M.

J Clin Apher. 2013 Oct;28(5):359-67. doi: 10.1002/jca.21280. Epub 2013 Jun 14.

PMID:
23765597
9.

Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization.

Chen AI, Bains T, Murray S, Knight R, Shoop K, Bubalo J, Fowler C, Slater S, Maziarz RT.

Bone Marrow Transplant. 2012 Dec;47(12):1526-9. doi: 10.1038/bmt.2012.74. Epub 2012 May 7.

PMID:
22562080
10.

Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.

Maziarz RT, Nademanee AP, Micallef IN, Stiff PJ, Calandra G, Angell J, Dipersio JF, Bolwell BJ.

Biol Blood Marrow Transplant. 2013 Apr;19(4):670-5. doi: 10.1016/j.bbmt.2013.01.005. Epub 2013 Jan 17.

11.

Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.

Milone G, Martino M, Spadaro A, Leotta S, Di Marco A, Scalzulli P, Cupri A, Di Martina V, Schinocca E, Spina E, Tripepi G.

Br J Haematol. 2014 Jan;164(1):113-23. doi: 10.1111/bjh.12606. Epub 2013 Oct 21.

PMID:
24138497
12.

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G; 3101 Investigators.

J Clin Oncol. 2009 Oct 1;27(28):4767-73. doi: 10.1200/JCO.2008.20.7209. Epub 2009 Aug 31.

PMID:
19720922
13.

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.

Stewart DA, Smith C, MacFarland R, Calandra G.

Biol Blood Marrow Transplant. 2009 Jan;15(1):39-46. doi: 10.1016/j.bbmt.2008.10.018.

14.

Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.

Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E, Olivieri A.

Biol Blood Marrow Transplant. 2012 Feb;18(2):241-9. doi: 10.1016/j.bbmt.2011.07.014. Epub 2011 Jul 24.

15.
16.

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.

Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G.

Biol Blood Marrow Transplant. 2009 Feb;15(2):249-56. doi: 10.1016/j.bbmt.2008.11.028.

17.

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF.

Biol Blood Marrow Transplant. 2008 Sep;14(9):1045-56. doi: 10.1016/j.bbmt.2008.07.004.

18.

Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.

Yuan S, Nademanee A, Kaniewski M, Palmer J, Shayani S, Wang S.

Transfusion. 2014 Aug;54(8):2015-21. doi: 10.1111/trf.12594. Epub 2014 Mar 24.

PMID:
24660786
19.

A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.

Lefrère F, Mauge L, Réa D, Ribeil JA, Dal Cortivo L, Brignier AC, Aoun C, Larghéro J, Cavazzana-Calvo M, Micléa JM.

Transfusion. 2013 Mar;53(3):564-9. doi: 10.1111/j.1537-2995.2012.03744.x. Epub 2012 Jun 21.

PMID:
22725259
20.

Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.

Arcaini L, Laszlo D, Rizzi S, Balzarotti M, Antoniazzi F, Zilioli VR, Guggiari E, Farina L, Todisco E, Bonfichi M, Alamos SM, Rossi G, Martinelli G, Morra E.

Leuk Res. 2011 Jun;35(6):712-4. doi: 10.1016/j.leukres.2010.12.036. Epub 2011 Jan 26.

PMID:
21276613

Supplemental Content

Support Center